The Claim
In patients with coronary artery disease who are already receiving statin therapy, the addition of either ezetimibe or a PCSK-9 inhibitor leads to a 19% reduction in the risk of major cardiovascular events, with a 19% lower risk of myocardial infarction and a 23% lower risk of ischemic stroke, indicating that intensified lipid-lowering therapy provides clinically meaningful protection against atherosclerotic complications.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with heart artery disease already taking cholesterol pills, adding one of two other types of cholesterol drugs helps lower their chances of heart attacks and strokes — especially strokes — and gives extra protection for their heart health.
See the scientific wording
In patients with coronary artery disease receiving statin therapy, adding ezetimibe or a PCSK-9 inhibitor reduces the risk of cardiovascular events by 19%, with a similar reduction in myocardial infarction (19% lower risk) and a greater reduction in ischemic stroke (23% lower risk), indicating that intensified lipid-lowering therapy provides meaningful protection against major atherosclerotic complications.
What the research says
1 studyStudy: Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events
The study looked at adding ezetimibe or PCSK-9 inhibitors to statins in heart disease patients and found they reduced heart attacks and strokes by about the amounts claimed.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.